Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Preclinical Evaluation of AZ12601011 and AZ12799734, Inhibitors of Transforming Growth Factor β Superfamily Type 1 Receptors.

Spender LC, Ferguson GJ, Hughes GD, Davies BR, Goldberg FW, Herrera B, Taylor RG, Strathearn LS, Sansom OJ, Barry ST, Inman GJ.

Mol Pharmacol. 2019 Feb;95(2):222-234. doi: 10.1124/mol.118.112946. Epub 2018 Nov 20.

PMID:
30459156
2.

The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature.

Inman GJ, Wang J, Nagano A, Alexandrov LB, Purdie KJ, Taylor RG, Sherwood V, Thomson J, Hogan S, Spender LC, South AP, Stratton M, Chelala C, Harwood CA, Proby CM, Leigh IM.

Nat Commun. 2018 Sep 10;9(1):3667. doi: 10.1038/s41467-018-06027-1.

3.

The Role of Human Papillomaviruses and Polyomaviruses in BRAF-Inhibitor Induced Cutaneous Squamous Cell Carcinoma and Benign Squamoproliferative Lesions.

Purdie KJ, Proby CM, Rizvi H, Griffin H, Doorbar J, Sommerlad M, Feltkamp MC, der Meijden EV, Inman GJ, South AP, Leigh IM, Harwood CA.

Front Microbiol. 2018 Aug 14;9:1806. doi: 10.3389/fmicb.2018.01806. eCollection 2018.

4.

Reduced SMAD2/3 activation independently predicts increased depth of human cutaneous squamous cell carcinoma.

Rose AM, Spender LC, Stephen C, Mitchell A, Rickaby W, Bray S, Evans AT, Dayal J, Purdie KJ, Harwood CA, Proby CM, Leigh IM, Coates PJ, Inman GJ.

Oncotarget. 2018 Feb 22;9(18):14552-14566. doi: 10.18632/oncotarget.24545. eCollection 2018 Mar 6.

5.

Treating the placenta to prevent adverse effects of gestational hypoxia on fetal brain development.

Phillips TJ, Scott H, Menassa DA, Bignell AL, Sood A, Morton JS, Akagi T, Azuma K, Rogers MF, Gilmore CE, Inman GJ, Grant S, Chung Y, Aljunaidy MM, Cooke CL, Steinkraus BR, Pocklington A, Logan A, Collett GP, Kemp H, Holmans PA, Murphy MP, Fulga TA, Coney AM, Akashi M, Davidge ST, Case CP.

Sci Rep. 2017 Aug 22;7(1):9079. doi: 10.1038/s41598-017-06300-1.

6.

TGFβ pathway limits dedifferentiation following WNT and MAPK pathway activation to suppress intestinal tumourigenesis.

Cammareri P, Vincent DF, Hodder MC, Ridgway RA, Murgia C, Nobis M, Campbell AD, Varga J, Huels DJ, Subramani C, Prescott KLH, Nixon C, Hedley A, Barry ST, Greten FR, Inman GJ, Sansom OJ.

Cell Death Differ. 2017 Oct;24(10):1681-1693. doi: 10.1038/cdd.2017.92. Epub 2017 Jun 16.

7.

Targeting BRAF-mutant tumours with TGFBR1 inhibitors.

Spender LC, Inman GJ.

Aging (Albany NY). 2017 Jan 31;9(1):5-6. doi: 10.18632/aging.101169. No abstract available.

8.

TNFα drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling.

Hurst LA, Dunmore BJ, Long L, Crosby A, Al-Lamki R, Deighton J, Southwood M, Yang X, Nikolic MZ, Herrera B, Inman GJ, Bradley JR, Rana AA, Upton PD, Morrell NW.

Nat Commun. 2017 Jan 13;8:14079. doi: 10.1038/ncomms14079.

9.

Fatal attractions? Correlations of CXCL12-CXCR4-CXCR7 expression with disease progression in melanoma and Kaposi sarcoma.

Spender LC, Inman GJ.

Br J Dermatol. 2016 Dec;175(6):1140-1141. doi: 10.1111/bjd.15136. No abstract available.

PMID:
27996149
10.

Loss of TGF-β signaling drives cSCC from skin stem cells - More evidence.

Rose AM, Sansom OJ, Inman GJ.

Cell Cycle. 2017 Mar 4;16(5):386-387. doi: 10.1080/15384101.2016.1259892. Epub 2016 Nov 18. No abstract available.

11.

Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.

Spender LC, Ferguson GJ, Liu S, Cui C, Girotti MR, Sibbet G, Higgs EB, Shuttleworth MK, Hamilton T, Lorigan P, Weller M, Vincent DF, Sansom OJ, Frame M, Dijke PT, Marais R, Inman GJ.

Oncotarget. 2016 Dec 13;7(50):81995-82012. doi: 10.18632/oncotarget.13226.

12.

Inactivation of TGFβ receptors in stem cells drives cutaneous squamous cell carcinoma.

Cammareri P, Rose AM, Vincent DF, Wang J, Nagano A, Libertini S, Ridgway RA, Athineos D, Coates PJ, McHugh A, Pourreyron C, Dayal JH, Larsson J, Weidlich S, Spender LC, Sapkota GP, Purdie KJ, Proby CM, Harwood CA, Leigh IM, Clevers H, Barker N, Karlsson S, Pritchard C, Marais R, Chelala C, South AP, Sansom OJ, Inman GJ.

Nat Commun. 2016 Aug 25;7:12493. doi: 10.1038/ncomms12493.

13.

Exosome-mediated transfer from the tumor microenvironment increases TGFβ signaling in squamous cell carcinoma.

Languino LR, Singh A, Prisco M, Inman GJ, Luginbuhl A, Curry JM, South AP.

Am J Transl Res. 2016 May 15;8(5):2432-7. eCollection 2016.

14.

The Promise of Genomics and the Development of Targeted Therapies for Cutaneous Squamous Cell Carcinoma.

Harwood CA, Proby CM, Inman GJ, Leigh IM.

Acta Derm Venereol. 2016 Jan;96(1):3-16. doi: 10.2340/00015555-2181. Review.

15.

E3 ubiquitin ligase HOIP attenuates apoptotic cell death induced by cisplatin.

MacKay C, Carroll E, Ibrahim AFM, Garg A, Inman GJ, Hay RT, Alpi AF.

Cancer Res. 2014 Apr 15;74(8):2246-2257. doi: 10.1158/0008-5472.CAN-13-2131. Epub 2014 Mar 31.

16.

Developments in Burkitt's lymphoma: novel cooperations in oncogenic MYC signaling.

Spender LC, Inman GJ.

Cancer Manag Res. 2014 Jan 9;6:27-38. doi: 10.2147/CMAR.S37745. Review.

17.

BMP9 is a proliferative and survival factor for human hepatocellular carcinoma cells.

Herrera B, García-Álvaro M, Cruz S, Walsh P, Fernández M, Roncero C, Fabregat I, Sánchez A, Inman GJ.

PLoS One. 2013 Jul 23;8(7):e69535. doi: 10.1371/journal.pone.0069535. Print 2013.

18.

A complex secretory program orchestrated by the inflammasome controls paracrine senescence.

Acosta JC, Banito A, Wuestefeld T, Georgilis A, Janich P, Morton JP, Athineos D, Kang TW, Lasitschka F, Andrulis M, Pascual G, Morris KJ, Khan S, Jin H, Dharmalingam G, Snijders AP, Carroll T, Capper D, Pritchard C, Inman GJ, Longerich T, Sansom OJ, Benitah SA, Zender L, Gil J.

Nat Cell Biol. 2013 Aug;15(8):978-90. doi: 10.1038/ncb2784. Epub 2013 Jun 16.

19.

Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma.

Lo Nigro C, Wang H, McHugh A, Lattanzio L, Matin R, Harwood C, Syed N, Hatzimichael E, Briasoulis E, Merlano M, Evans A, Thompson A, Leigh I, Fleming C, Inman GJ, Proby C, Crook T.

J Invest Dermatol. 2013 May;133(5):1278-85. doi: 10.1038/jid.2012.493. Epub 2013 Feb 14.

20.

Exogenous heparin binds and inhibits bone morphogenetic protein 6 biological activity.

Brkljacic J, Pauk M, Erjavec I, Cipcic A, Grgurevic L, Zadro R, Inman GJ, Vukicevic S.

Int Orthop. 2013 Mar;37(3):529-41. doi: 10.1007/s00264-012-1714-3. Epub 2013 Jan 10.

21.

Transforming growth factor-β directly induces p53-up-regulated modulator of apoptosis (PUMA) during the rapid induction of apoptosis in myc-driven B-cell lymphomas.

Spender LC, Carter MJ, O'Brien DI, Clark LJ, Yu J, Michalak EM, Happo L, Cragg MS, Inman GJ.

J Biol Chem. 2013 Feb 15;288(7):5198-209. doi: 10.1074/jbc.M112.410274. Epub 2012 Dec 14.

22.

Crosstalk between p53 and TGF-β Signalling.

Elston R, Inman GJ.

J Signal Transduct. 2012;2012:294097. doi: 10.1155/2012/294097. Epub 2012 Mar 28.

23.

NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity.

Wang H, Lee S, Nigro CL, Lattanzio L, Merlano M, Monteverde M, Matin R, Purdie K, Mladkova N, Bergamaschi D, Harwood C, Syed N, Szlosarek P, Briasoulis E, McHugh A, Thompson A, Evans A, Leigh I, Fleming C, Inman GJ, Hatzimichael E, Proby C, Crook T.

Br J Cancer. 2012 Apr 10;106(8):1446-52. doi: 10.1038/bjc.2012.95. Epub 2012 Mar 27.

24.

Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics.

Spender LC, Inman GJ.

Mol Cancer Res. 2012 Mar;10(3):347-59. doi: 10.1158/1541-7786.MCR-11-0394. Epub 2012 Jan 12.

25.

Inhibition of germinal centre apoptotic programmes by epstein-barr virus.

Spender LC, Inman GJ.

Adv Hematol. 2011;2011:829525. doi: 10.1155/2011/829525. Epub 2011 Oct 23.

26.

Switching TGFβ from a tumor suppressor to a tumor promoter.

Inman GJ.

Curr Opin Genet Dev. 2011 Feb;21(1):93-9. doi: 10.1016/j.gde.2010.12.004. Epub 2011 Jan 19. Review.

PMID:
21251810
27.

Regulation of cell proliferation and apoptosis in neuroblastoma cells by ccp1, a FGF2 downstream gene.

Pellicano F, Thomson RE, Inman GJ, Iwata T.

BMC Cancer. 2010 Nov 30;10:657. doi: 10.1186/1471-2407-10-657.

28.

Differing contributions of LIMK and ROCK to TGFβ-induced transcription, motility and invasion.

Morin P, Wickman G, Munro J, Inman GJ, Olson MF.

Eur J Cell Biol. 2011 Jan;90(1):13-25. doi: 10.1016/j.ejcb.2010.09.009. Epub 2010 Nov 11.

PMID:
21074289
29.

Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter.

Hannigan A, Smith P, Kalna G, Lo Nigro C, Orange C, O'Brien DI, Shah R, Syed N, Spender LC, Herrera B, Thurlow JK, Lattanzio L, Monteverde M, Maurer ME, Buffa FM, Mann J, Chu DC, West CM, Patridge M, Oien KA, Cooper JA, Frame MC, Harris AL, Hiller L, Nicholson LJ, Gasco M, Crook T, Inman GJ.

J Clin Invest. 2010 Aug;120(8):2842-57. doi: 10.1172/JCI36125. Epub 2010 Jul 1.

30.

Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation.

Herrera B, van Dinther M, Ten Dijke P, Inman GJ.

Cancer Res. 2009 Dec 15;69(24):9254-62. doi: 10.1158/0008-5472.CAN-09-2912.

31.

Targeting the BCL-2 family in malignancies of germinal centre origin.

Spender LC, Inman GJ.

Expert Opin Ther Targets. 2009 Dec;13(12):1459-72. doi: 10.1517/14728220903379565. Review.

PMID:
19922301
33.

TGF-beta induces apoptosis in human B cells by transcriptional regulation of BIK and BCL-XL.

Spender LC, O'Brien DI, Simpson D, Dutt D, Gregory CD, Allday MJ, Clark LJ, Inman GJ.

Cell Death Differ. 2009 Apr;16(4):593-602. doi: 10.1038/cdd.2008.183. Epub 2009 Jan 9.

34.

TGF-beta-mediated activation of RhoA signalling is required for efficient (V12)HaRas and (V600E)BRAF transformation.

Fleming YM, Ferguson GJ, Spender LC, Larsson J, Karlsson S, Ozanne BW, Grosse R, Inman GJ.

Oncogene. 2009 Feb 19;28(7):983-93. doi: 10.1038/onc.2008.449. Epub 2008 Dec 15.

PMID:
19079344
35.

TGF-beta induces growth arrest in Burkitt lymphoma cells via transcriptional repression of E2F-1.

Spender LC, Inman GJ.

J Biol Chem. 2009 Jan 16;284(3):1435-42. doi: 10.1074/jbc.M808080200. Epub 2008 Nov 19.

36.

NCAM is at the heart of reciprocal regulation of E-cadherin- and integrin-mediated adhesions via signaling modulation.

Frame MC, Inman GJ.

Dev Cell. 2008 Oct;15(4):494-6. doi: 10.1016/j.devcel.2008.09.016. Review.

37.

Linking Smads and transcriptional activation.

Inman GJ.

Biochem J. 2005 Feb 15;386(Pt 1):e1-e3.

38.

Stoichiometry of active smad-transcription factor complexes on DNA.

Inman GJ, Hill CS.

J Biol Chem. 2002 Dec 27;277(52):51008-16. Epub 2002 Oct 8. Erratum in: J Biol Chem. 2003 May 9;278(19):17580.

39.
40.

SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.

Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS.

Mol Pharmacol. 2002 Jul;62(1):65-74.

PMID:
12065756
42.

Different Smad2 partners bind a common hydrophobic pocket in Smad2 via a defined proline-rich motif.

Randall RA, Germain S, Inman GJ, Bates PA, Hill CS.

EMBO J. 2002 Jan 15;21(1-2):145-56.

43.
46.

The AMPA receptor GluR2 C terminus can mediate a reversible, ATP-dependent interaction with NSF and alpha- and beta-SNAPs.

Osten P, Srivastava S, Inman GJ, Vilim FS, Khatri L, Lee LM, States BA, Einheber S, Milner TA, Hanson PI, Ziff EB.

Neuron. 1998 Jul;21(1):99-110.

48.
49.

Human papillomaviruses, tumour suppressor genes and cervical cancer.

Inman GJ, Cook ID, Lau RK.

Int J STD AIDS. 1993 May-Jun;4(3):128-34.

PMID:
8391853
50.

Cell growth effects of Epstein-Barr virus leader protein.

Allan GJ, Inman GJ, Parker BD, Rowe DT, Farrell PJ.

J Gen Virol. 1992 Jun;73 ( Pt 6):1547-51.

PMID:
1318948

Supplemental Content

Loading ...
Support Center